Position in SVRA
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,532,115
+$466,995 QoQ
Shares Held
248,720
+27.5% QoQ
Ownership
0.121%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#59
of 181 holders
Holding Since
Jun 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. SVRA ranks #49 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in SVRA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,532,115 | 248,720 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $1,065,120 | 195,077 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $905,006 | 150,084 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $324,944 | 91,021 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $574,218 | 207,299 | Shares | Sole | 2025-05-14 | |
| 2024-06-30 | $413,220 | 102,536 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $5,108,678 | 1,025,839 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $417,952 | 88,926 | Shares | Sole | 2024-02-14 | |
| 2021-06-30 | $32,636 | 19,198 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||